Ipamorelin Dosing Protocol

Ipamorelin (also called NNC 26-0161) is a research peptide that signals your body to release its own growth hormone in natural pulses. It belongs to a class of compounds called growth hormone secretagogues -- substances that trigger GH release rather than injecting GH directly. Novo Nordisk originally developed it in the late 1990s, and it has since become one of the most widely used growth hormone-releasing peptides in research settings.

Structurally, Ipamorelin is a small peptide made of five amino acids, engineered from an earlier compound (GHRP-1) to be smaller, more stable, and more selective. Its plasma half-life is approximately 2 hours, meaning the body clears it relatively quickly after each dose.

What makes Ipamorelin stand out is its clean hormonal profile. Most growth hormone-releasing peptides also raise cortisol (a stress hormone), prolactin, and other hormones as unwanted side effects. Ipamorelin does not -- even at doses far above the level needed to trigger GH release, lab studies showed no meaningful rise in cortisol, prolactin, or other stress-related hormones. This selectivity is why it is often preferred over alternatives like GHRP-2 and GHRP-6.

Novo Nordisk's clinical program ultimately targeted a digestive condition (postoperative ileus) rather than GH-focused uses, and that program was discontinued after Phase II trials did not show efficacy for that endpoint. Ipamorelin is now widely available as a research compound, commonly explored for GH optimization, body composition, recovery, and anti-aging research.

This compound is not FDA-approved for any indication. All information on this page is for educational and research reference purposes only.

The table below shows how much bacteriostatic (BAC) water to add to each Ipamorelin vial size, the resulting concentration, and exactly how much liquid to draw for common doses. Find your vial size in the left column, then read across to your target dose to see the volume in milliliters and the corresponding syringe units on a standard U-100 insulin syringe.

Ipamorelin tends to cause fewer side effects than other growth hormone-releasing peptides because it does not raise cortisol, prolactin, or other stress hormones. That said, side effects can still occur -- especially at higher doses or during early use.

Common side effects: Community protocols most often report mild headache, transient water retention or bloating, and mild appetite increase.

Clinical tolerability context: In Beck et al. 2014 postoperative ileus trial context, treatment-emergent adverse event rates were not worse than placebo.

GH-related effects: At higher doses or extended use, some reports describe mild joint stiffness, tingling in extremities, or transient fatigue consistent with elevated GH/IGF-1 signaling.

Injection site reactions: Temporary redness, stinging, or minor swelling can occur. Site rotation and sterile technique reduce frequency.

Cortisol and hormonal side effects: Unlike GHRP-2 and GHRP-6, Ipamorelin did not cause meaningful increases in cortisol (a stress hormone), ACTH, or prolactin in laboratory testing at standard GH-releasing doses. This cleaner hormonal profile is the primary reason it is considered better tolerated.

Contraindications and monitoring: Avoid use in active malignancy, uncontrolled glycemic disease, severe cardiovascular disease, and pregnancy or breastfeeding. Consider periodic fasting glucose and HbA1c monitoring for extended protocols. Ipamorelin and ghrelin mimetics are prohibited substances under WADA anti-doping rules.

The table below summarizes all major published studies on Ipamorelin. Most of the research focused on understanding how the compound behaves in the body (pharmacokinetics) and testing it for a digestive condition -- not for the GH-related uses it is commonly explored for today.

Here is the key takeaway: Ipamorelin's clinical research was limited and focused on the wrong indication for what most people care about today. Early studies in the late 1990s confirmed that Ipamorelin does release growth hormone selectively and has a short half-life of about 2 hours. But when Novo Nordisk moved to Phase II trials, they tested it for speeding up gut recovery after surgery -- not for GH optimization, body composition, or anti-aging. The compound did not work well enough for that digestive indication, and the program was discontinued.

No clinical trials have ever evaluated Ipamorelin for the body-composition, recovery, or anti-aging purposes it is commonly explored for in research settings. The dosing protocols used in those contexts are community-derived, not clinically validated.

Ipamorelin, GHRP-6, and GHRP-2 all belong to the same family -- they activate the same growth hormone receptor. The main difference is side effects. Ipamorelin releases GH without raising cortisol or prolactin, while the other two do. The table below breaks down the key differences so you can see how they compare on the metrics that matter most: potency, hormonal side effects, appetite effects, and dosing frequency.

These compounds target the same receptor family but differ in endocrine spillover profiles. Ipamorelin's defining feature is GH release without the cortisol, ACTH, and prolactin elevation commonly associated with GHRP-2 and GHRP-6.

GHRP-6 may be preferred where appetite stimulation is desirable, while GHRP-2 is often selected for GH potency per microgram despite cleaner-profile tradeoffs.

Reconstitution concentration and syringe math differ by vial and protocol. Verify concentration-specific draws before administration.

See the GHRP-6, GHRP-2, CJC-1295 (with DAC) and CJC-1295 (No DAC) for compound-specific guides.